NiQuitin CQ reclassification
This article was originally published in The Tan Sheet
GlaxoSmithKline seeks to change status of its 4 mg nicotine replacement therapy lozenges from Pharmacy to General Sale List in the UK, according to Feb. 10 filing with the Medicines Control Agency. GSK states NRT should be as "freely available" as nicotine, points out most NRT products already have GSL status. "Wider availability of NiQuitin CQ...is likely to lead to increased numbers of smokers stopping," petition says. Comments are due March 24...
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”